Which studies validate polivy's effectiveness?

Polivy (polatuzumab vedotin) has been studied in a few key trials that support its effectiveness, mainly in diffuse large B-cell lymphoma (DLBCL) across different settings. Here are the pivotal studies:

- ROMULUS (Phase II randomized trial)
- Setting: Relapsed/refractory DLBCL after at least one prior therapy
- Design: Polatuzumab vedotin plus bendamustine and rituximab (pola-BR) vs bendamustine + rituximab (BR) alone
- Takeaway: pola-BR improved response rates and progression-free survival versus BR alone, demonstrating added activity of polatuzumab in this setting.

- POLARIX (Phase III trial)
- Setting: Newly diagnosed, previously untreated DLBCL
- Design: Polatuzumab vedotin substituted for vincristine in R-CHOP (pola-R-CHP) vs standard R-CHOP
- Takeaway: Improved progression-free survival (PFS) with pola-R-CHP and a similar safety profile; results led to regulatory use of pola-R-CHP in first-line DLBCL in many regions (status varies by country).

- Earlier/phase II data (supporting efficacy signals)
- Various single-arm or small randomized studies in R/R DLBCL and related B-cell lymphomas showed meaningful activity when pola-vedotin was combined with BR or other regimens, providing the basis for the larger ROMULUS and POLARIS trials.

Notes and next steps:
- If you’re interested in a specific setting (first-line vs relapse) or a particular regulatory region (FDA/EMA approvals), I can pull the exact trial citations, DOIs, and summaries.
- I can also provide a quick-reading list of the primary publications (authors, journals, years) and relevant FDA/EMA labeling details if you’d like.
- If you’re considering this information for clinical decisions, consult the latest guidelines and the current drug label for dosing, indications, and safety.

Would you like me to fetch the exact references or focus on one setting?